No abstract

No abstract

No abstract

No abstract

No abstract

Over a period of four years, stage 1 hypertension developed in nearly two thirds of patients with untreated prehypertension (the placebo group). Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension during the study period. Thus, treatment of prehypertension appears to be feasible. (ClinicalTrials.gov number, NCT00227318.).

EFT VENTRICULAR HYPERTROphy (LVH) detected by 12lead electrocardiogram (ECG) 1-3 and by echocardiography 4-8 are common manifestations of preclinical cardiovascular (CV) disease that strongly predict CV morbidity and mortality. Antihypertensive therapy aimed at reducing blood pressure (BP) can produce regression of LVH 3,4,9-15 and reduces but does not entirely eliminate the increased risk of major CV events. 16-20 However, whether regression of electrocardiographic LVH per se is associated with improved prognosis independent of improvements in See also pp 2350 and 2396 and Patient Page.

No abstract